← Back
$RAPP All transactions

Rapport Therapeutics, Inc.

▼ SELL 10b5-1 Plan

$ Value

$1.0M

Shares

39,435

Price

$26

Filed

Sep 19

Insider

Name

Ceesay Abraham

Title

Chief Executive Officer

CIK

0001722140

Roles

Director Officer

Transaction Details

Transaction Date

2025-09-17

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

586,812

Footnotes

These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.74 to $27.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.78 to $26.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.02 to $27.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Filing Info

Accession No.

0001193125-25-209062

Form Type

4

Issuer CIK

0002012593

Ceesay Abraham's History

Date Ticker Type Value
2025-12-17 RAPP $70K
2025-12-17 RAPP $84K
2025-12-17 RAPP $19K
2025-12-17 RAPP $62K
2025-12-17 RAPP $73K
2025-12-17 RAPP $16K
2025-11-17 RAPP $69K
2025-11-17 RAPP $78K
2025-11-17 RAPP $56K
2025-11-17 RAPP $72K

Other Insiders at RAPP (90d)

Insider Bought Sold Last
Third Rock Ventures V, L.P. $17.2M 2026-04-17
Gault Cheryl
Chief Operating Officer
$282K 2026-03-30
Yeleswaram Krishnaswamy
Chief Development Officer
$1.8M 2026-04-17